Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Helena Müller-Kräuter"'
Autor:
Philip J.M. Brouwer, Hailee R. Perrett, Tim Beaumont, Haye Nijhuis, Sabine Kruijer, Judith A. Burger, Ilja Bontjer, Wen-Hsin Lee, James A. Ferguson, Martin Schauflinger, Helena Müller-Kräuter, Rogier W. Sanders, Thomas Strecker, Marit J. van Gils, Andrew B. Ward
Publikováno v:
Cell Reports, Vol 43, Iss 9, Pp 114708- (2024)
Summary: Lassa fever continues to be a major public health burden in West Africa, yet effective therapies or vaccines are lacking. The isolation of protective neutralizing antibodies against the Lassa virus glycoprotein complex (GPC) justifies the de
Externí odkaz:
https://doaj.org/article/6024a95cb789487bbd0a23b8611ae42e
Autor:
Hailee R. Perrett, Philip J.M. Brouwer, Jonathan Hurtado, Maddy L. Newby, Lin Liu, Helena Müller-Kräuter, Sarah Müller Aguirre, Judith A. Burger, Joey H. Bouhuijs, Grace Gibson, Terrence Messmer, John S. Schieffelin, Aleksandar Antanasijevic, Geert-Jan Boons, Thomas Strecker, Max Crispin, Rogier W. Sanders, Bryan Briney, Andrew B. Ward
Publikováno v:
Cell Reports, Vol 42, Iss 5, Pp 112524- (2023)
Summary: Lassa fever is an acute hemorrhagic fever caused by the zoonotic Lassa virus (LASV). The LASV glycoprotein complex (GPC) mediates viral entry and is the sole target for neutralizing antibodies. Immunogen design is complicated by the metastab
Externí odkaz:
https://doaj.org/article/42bc3a303aa044c8bb858af2181c5575
Publikováno v:
Viruses, Vol 15, Iss 7, p 1436 (2023)
Background: Lassa virus (LASV) can cause severe acute systemic infection in humans. No approved antiviral drugs or vaccines are currently available. Antibody-based therapeutics are considered a promising treatment strategy in the management of LASV d
Externí odkaz:
https://doaj.org/article/86aff6124d8a4bd8aee511aa91240792
Autor:
Philip J.M. Brouwer, Aleksandar Antanasijevic, Adam J. Ronk, Helena Müller-Kräuter, Yasunori Watanabe, Mathieu Claireaux, Hailee R. Perrett, Tom P.L. Bijl, Marloes Grobben, Jeffrey C. Umotoy, Angela I. Schriek, Judith A. Burger, Khadija Tejjani, Nicole M. Lloyd, Thijs H. Steijaert, Marlies M. van Haaren, Kwinten Sliepen, Steven W. de Taeye, Marit J. van Gils, Max Crispin, Thomas Strecker, Alexander Bukreyev, Andrew B. Ward, Rogier W. Sanders
Publikováno v:
Cell host & microbe, 30(12), 1759-1772.e12. Cell Press
The Lassa virus is endemic in parts of West Africa, and it causes hemorrhagic fever with high mortality. The development of a recombinant protein vaccine has been hampered by the instability of soluble Lassa virus glycoprotein complex (GPC) trimers,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d35920c6774cfa1a3575acd82410909f
https://eprints.soton.ac.uk/473593/
https://eprints.soton.ac.uk/473593/
Autor:
Philip J.M. Brouwer, Aleksandar Antanasijevic, Adam J. Ronk, Helena Müller-Kräuter, Yasunori Watanabe, Mathieu Claireaux, Nicole M. Lloyd, Tom. P. L. Bijl, Hailee R. Perrett, Thijs Steijaert, Judith A. Burger, Marlies M. van Haaren, Kwinten Sliepen, Marit J. van Gils, Max Crispin, Thomas Strecker, Alexander Bukreyev, Andrew B. Ward, Rogier W. Sanders
Lassa virus is endemic in large parts of West Africa and causes a hemorrhagic fever. Recent years have seen several serious outbreaks of Lassa fever with high mortality rates. A vaccine to curtail infection is urgently needed. The development of a re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::164ec01d4e0b674a597ba94f79c1e342
https://doi.org/10.1101/2022.03.28.486091
https://doi.org/10.1101/2022.03.28.486091
Autor:
Addi J. Romero-Olmedo, Axel Ronald Schulz, Svenja Hochstätter, Dennis Das Gupta, Heike Hirseland, Daniel Staudenraus, Bärbel Camara, Kirsten Volland, Véronique Hefter, Siddhesh Sapre, Verena Krähling, Helena Müller-Kräuter, Henrik E. Mei, Christian Keller, Michael Lohoff
A third mRNA-based “booster” vaccination is the favored strategy to maintain protection against SARS-CoV-2 infection. Yet, significant waning of specific immunity within six months after 2nd vaccination, along with higher incidence of breakthroug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d8160cd519cec4fc425887a79c9d7b0
https://doi.org/10.1101/2022.02.10.22270733
https://doi.org/10.1101/2022.02.10.22270733
Autor:
Addi J, Romero-Olmedo, Axel Ronald, Schulz, Svenja, Hochstätter, Dennis Das, Gupta, Heike, Hirseland, Daniel, Staudenraus, Bärbel, Camara, Kirsten, Volland, Véronique, Hefter, Siddhesh, Sapre, Verena, Krähling, Helena, Müller-Kräuter, Ho-Ryun, Chung, Henrik E, Mei, Christian, Keller, Michael, Lohoff
Publikováno v:
The Lancet Infectious Diseases. 22:588-589
Autor:
Addi J. Romero-Olmedo, Axel Ronald Schulz, Svenja Hochstätter, Dennis Das Gupta, Iiris Virta, Heike Hirseland, Daniel Staudenraus, Bärbel Camara, Carina Münch, Véronique Hefter, Siddhesh Sapre, Verena Krähling, Helena Müller-Kräuter, Marek Widera, Henrik E. Mei, Christian Keller, Michael Lohoff
Publikováno v:
Nature microbiology
Here we compared SARS-CoV-2-specific antibody and T-cell responses between older adults (80 years old, n = 51) and a younger control group (20-53 years old, n = 46) after receiving two doses of BNT162b2. We found that responses in older adults were g
Autor:
Andrew J. Blok, Pratik Gurnani, Thomas Strecker, Helena Müller-Kräuter, Morgan R. Alexander, Jonathan K. Ball, Cameron Alexander, Alex Xenopoulos, Theocharis Tsoleridis, Joshua D. Duncan, Richard A. Urbanowicz, Laurence Burroughs
Publikováno v:
Biointerphases
The emergence of SARS-CoV-2 highlights the global need for platform technologies to enable the rapid development of diagnostics, vaccines, treatments, and personal protective equipment (PPE). However, many current technologies require the detailed me